AGP Picks
View all

Humulin market seen reaching $46.65 million by 2030

Nov. 4, 2026
Humulin market seen reaching $46.65 million by 2030
By AI, Created 14:45 UTC, Nov 04, 2026, AGP -

The Business Research Company says the global market for Humulin, a recombinant human insulin, is on track to grow from $34.09 million in 2025 to $46.65 million by 2030. Rising diabetes rates, broader insulin access and demand for lower-cost treatment options are shaping the outlook across North America, Asia-Pacific and other major regions.

Why it matters: - Humulin remains an essential insulin option for diabetes care, especially where cost, access and supply reliability matter most. - The market outlook signals continued demand for human insulin therapies as diabetes prevalence rises worldwide. - Growth in hospital pharmacy infrastructure and insulin subsidy programs could widen access to treatment in more markets.

What happened: - The Business Research Company released an analysis of the Humulin (recombinant human insulin) market on November 4, 2026. - The report projects the market will rise from $34.09 million in 2025 to $36.38 million in 2026. - The same analysis forecasts the market will reach $46.65 million by 2030. - The report points to a 6.7% CAGR from 2025 to 2026 and a 6.4% CAGR over the longer forecast period. - North America held the largest share of the Humulin market in 2025. - Asia-Pacific is projected to be the fastest-growing region through the forecast period. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Humulin is a biotechnology-derived insulin that matches natural human insulin. - Producers make Humulin by inserting the human insulin gene into bacteria or yeast. - The insulin is primarily used to treat diabetes mellitus, including Type 1 and Type 2 diabetes. - Humulin helps regulate blood sugar, support glucose absorption and reduce complications linked to blood sugar imbalance. - The report identifies early recombinant insulin adoption, rising Type 1 diabetes cases, cost advantages over insulin analogues, physician familiarity and established manufacturing methods as key historical growth drivers. - The report highlights rising diabetes burdens in developing countries, government insulin subsidies, demand for dependable supply, hospital pharmacy expansion and the continued need for insulin therapy as forward growth drivers. - Expected market trends include continued demand for human insulin, stronger preference for premixed insulin formulations, broader insulin access programs and ongoing use in resource-constrained settings. - Diabetes UK reported in May 2024 that about 4.4 million people in the UK were diagnosed with diabetes in 2022-23. - Diabetes UK said about 8% of those cases were Type 1 diabetes and about 90% were Type 2 diabetes.

Between the lines: - The market appears to be growing on practicality more than novelty, with Humulin positioned as a dependable and often lower-cost option. - Personalized medicine is also supporting demand because Humulin dosing can be adjusted to an individual patient’s needs and treatment response. - The report cites the broader move toward individualized therapies, including FDA approval of 16 new personalized treatments in 2023, up from six in 2022. - That broader precision-medicine trend may reinforce the role of insulin products that can be tailored without requiring highly complex delivery systems.

What's next: - Humulin demand is likely to track diabetes prevalence, especially in developing markets where access and affordability remain key barriers. - Growth may also depend on how quickly governments expand subsidy programs and healthcare systems improve pharmacy distribution. - The report’s regional split suggests Asia-Pacific could contribute an increasing share of future market expansion. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspot infographics, and updated trend analysis.

The bottom line: - Humulin’s market is expanding steadily because diabetes care still depends on reliable, affordable insulin, and that need is likely to persist through 2030.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Global European

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Global European

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.